← Back to Clinical Trials
Recruiting NCT07558564

NCT07558564 Evaluation of Platelet-Rich Plasma (PRP) Treatment in Tendinopathies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07558564
Status Recruiting
Phase
Sponsor ReSport Clinic
Condition Patellar Tendinopathy
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2026-04
Primary Completion 2028-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Platelet rich plasma (PRP)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2026-04 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This multicenter, prospective, observational study, based on real-world evidence (RWE), aims to evaluate the efficacy and safety of Platelet-Rich Plasma (PRP) treatment across four types of tendinopathies: patellar, Achilles, epicondylar, and plantar fasciosis. Data collection and analysis will be conducted using the BioSmartData® platform, including hematology analyzers for PRP characterization, clinical variables, treatment protocols, and longitudinal assessment of therapeutic response.

Eligibility Criteria

Inclusion Criteria: * Clinical and/or ultrasound diagnosis of chronic tendinopathy (duration \>6 weeks) * Age \>18 years * Provision of written informed consent * Willingness and ability to complete follow-up assessments for 12 months Exclusion Criteria: * Surgical treatment of the affected tendon within the previous 6 months * Corticosteroid injection within the last month * Systemic inflammatory disease (e.g., rheumatoid arthritis) * Coagulopathies or ongoing anticoagulant therapy * Complete blood count showing a platelet concentration \<100 × 10⁹/L (to exclude patients with potential thrombocytopenia) * Pregnancy or breastfeeding

Contact & Investigator

Central Contact

Resport Clinic, MD PhD

✉ abat@resportclinic.com

📞 +34 93 2778709

Principal Investigator

Ferran Abat Gonzalez, MD PhD

PRINCIPAL INVESTIGATOR

ReSport Clinic

Frequently Asked Questions

Who can join the NCT07558564 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Patellar Tendinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07558564 currently recruiting?

Yes, NCT07558564 is actively recruiting participants. Contact the research team at abat@resportclinic.com for enrollment information.

Where is the NCT07558564 trial being conducted?

This trial is being conducted at A Coruña, Spain, Barcelona, Spain, Barcelona, Spain, Madrid, Spain and 1 additional location.

Who is sponsoring the NCT07558564 clinical trial?

NCT07558564 is sponsored by ReSport Clinic. The principal investigator is Ferran Abat Gonzalez, MD PhD at ReSport Clinic. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology